Related Experiment Videos
Risk-benefit of thrombolysis
1Thoraxcenter, University Hospital Rotterdam, The Netherlands.
Cardiology Clinics
|August 1, 1995
Summary
Thrombolytic therapy significantly reduces mortality, with the greatest absolute benefit seen in high-risk patients. Accelerated tissue plasminogen activator (TPA) offers additional advantages proportional to baseline risk, making it a valuable reperfusion strategy.
Area of Science:
- Cardiology
- Neurology
- Emergency Medicine
Background:
- Thrombolytic therapy is a cornerstone treatment for acute ischemic events.
- Previous studies indicate consistent relative mortality reductions across patient subgroups.
Purpose of the Study:
- To develop a predictive model for assessing the survival benefit and intracranial hemorrhage risk associated with thrombolytic therapy.
- To guide individualized risk/benefit assessments for reperfusion strategies.
Main Methods:
- Logistic regression analysis was employed to create predictive tables.
- Patient subgroups were analyzed based on baseline characteristics and expected mortality.
Main Results:
- The absolute mortality reduction from thrombolytic therapy is largest in patients with the highest expected mortality.
- The benefit of accelerated tissue plasminogen activator (TPA) is proportional to the patient's expected mortality.
- Predictive tables for survival benefit and intracranial hemorrhage risk were developed.
Conclusions:
- Thrombolytic therapy generally offers benefits that outweigh the risk of intracranial hemorrhage.
- Accelerated TPA provides advantages that exceed its slightly increased bleeding risk.
- The developed model aids in allocating reperfusion therapies based on individual patient risk and resource availability.